Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 35

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 35
---
11/2018
     
    5562900
     
    0081716-000037
     
    11-Sep-24
     
    Section
    8 & 15 Due
  
    United
    States of America
     
    ARAKODA
     
    Registered
     
    87688137
     
    16-Nov-17
     
    12/31/2019
     
    5950691
     
    0081716-000050
     
    31-Dec-25
     
    Section
    8 & 15 Due
  
    United
    States of America
     
    KODATEF
     
    Abandoned-
     
    90072885
     
    24-Jul-20

    0081716-000069
     
    16-Aug-23
     
    Statement of Use/3rd Extension of Time Due
  
    United  States
    of America
     
    KODATEF
     
    Allowed
     
    98/363,219    
     
    18-Jan-24

    0081716-000074
     
    12-May-25
     
    Statement
    of Use/1st Extension of Time Due

Key
Relationships & Licenses

On May 30, 2014, we entered into the Exclusive
License Agreement (the “2014 NUS-SHS Agreement”) with National University of Singapore (“NUS”) and Singapore
Health Services Pte Ltd (“SHS”) in which we were granted a license from NUS and SHS with respect to their share of patent
rights regarding “Dosing Regimen for Use of Celgosivir as an Antiviral Therapeutic for Dengue Virus Infection” to develop,
market and sell licensed products. The 2014 NUS-SHS Agreement continues in force until the expiration of the last to expire of any patents
under the patent rights unless terminated earlier in accordance with the 2014 NUS-SHS Agreement. We are obligated to pay royalties at
the rate of 1.5% of gross sales.

16

On July 15, 2015, we entered into the Exclusive
License Agreement with the U.S. Army Medical Materiel Development Activity (the “U.S. Army”), which was subsequently amended
(the “U.S.